251 related articles for article (PubMed ID: 20630752)
1. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.
Duffey MO; Adams R; Blackburn C; Chau RW; Chen S; Galvin KM; Garcia K; Gould AE; Greenspan PD; Harrison S; Huang SC; Kim MS; Kulkarni B; Langston S; Liu JX; Ma LT; Menon S; Nagayoshi M; Rowland RS; Vos TJ; Xu T; Yang JJ; Yu S; Zhang Q
Bioorg Med Chem Lett; 2010 Aug; 20(16):4800-4. PubMed ID: 20634068
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
Wenglowsky S; Ahrendt KA; Buckmelter AJ; Feng B; Gloor SL; Gradl S; Grina J; Hansen JD; Laird ER; Lunghofer P; Mathieu S; Moreno D; Newhouse B; Ren L; Risom T; Rudolph J; Seo J; Sturgis HL; Voegtli WC; Wen Z
Bioorg Med Chem Lett; 2011 Sep; 21(18):5533-7. PubMed ID: 21802293
[TBL] [Abstract][Full Text] [Related]
4. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
[TBL] [Abstract][Full Text] [Related]
5. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing.
Wenglowsky S; Moreno D; Rudolph J; Ran Y; Ahrendt KA; Arrigo A; Colson B; Gloor SL; Hastings G
Bioorg Med Chem Lett; 2012 Jan; 22(2):912-5. PubMed ID: 22209462
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
[TBL] [Abstract][Full Text] [Related]
7. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
[TBL] [Abstract][Full Text] [Related]
8. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
Buckmelter AJ; Ren L; Laird ER; Rast B; Miknis G; Wenglowsky S; Schlachter S; Welch M; Tarlton E; Grina J; Lyssikatos J; Brandhuber BJ; Morales T; Randolph N; Vigers G; Martinson M; Callejo M
Bioorg Med Chem Lett; 2011 Feb; 21(4):1248-52. PubMed ID: 21211972
[TBL] [Abstract][Full Text] [Related]
9. Non-oxime inhibitors of B-Raf(V600E) kinase.
Ren L; Wenglowsky S; Miknis G; Rast B; Buckmelter AJ; Ely RJ; Schlachter S; Laird ER; Randolph N; Callejo M; Martinson M; Galbraith S; Brandhuber BJ; Vigers G; Morales T; Voegtli WC; Lyssikatos J
Bioorg Med Chem Lett; 2011 Feb; 21(4):1243-7. PubMed ID: 21251822
[TBL] [Abstract][Full Text] [Related]
10. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
Gopalsamy A; Ciszewski G; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 May; 19(10):2735-8. PubMed ID: 19362830
[TBL] [Abstract][Full Text] [Related]
11. Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup.
Stellwagen JC; Adjabeng GM; Arnone MR; Dickerson SH; Han C; Hornberger KR; King AJ; Mook RA; Petrov KG; Rheault TR; Rominger CM; Rossanese OW; Smitheman KN; Waterson AG; Uehling DE
Bioorg Med Chem Lett; 2011 Aug; 21(15):4436-40. PubMed ID: 21733693
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel pyrrolopyrazoles as protein kinase C β II inhibitors.
Li H; Hong Y; Nukui S; Lou J; Johnson S; Scales S; Botrous I; Tompkins E; Yin C; Zhou R; He M; Jensen J; Bouzida D; Alton G; Lafontaine J; Grant S
Bioorg Med Chem Lett; 2011 Jan; 21(1):584-7. PubMed ID: 21084194
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
[TBL] [Abstract][Full Text] [Related]
14. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
[TBL] [Abstract][Full Text] [Related]
16. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
[TBL] [Abstract][Full Text] [Related]
17. Non-oxime pyrazole based inhibitors of B-Raf kinase.
Newhouse BJ; Hansen JD; Grina J; Welch M; Topalov G; Littman N; Callejo M; Martinson M; Galbraith S; Laird ER; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
Bioorg Med Chem Lett; 2011 Jun; 21(11):3488-92. PubMed ID: 21536432
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.
Smith AL; DeMorin FF; Paras NA; Huang Q; Petkus JK; Doherty EM; Nixey T; Kim JL; Whittington DA; Epstein LF; Lee MR; Rose MJ; Babij C; Fernando M; Hess K; Le Q; Beltran P; Carnahan J
J Med Chem; 2009 Oct; 52(20):6189-92. PubMed ID: 19764794
[TBL] [Abstract][Full Text] [Related]
19. Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors.
Vasbinder MM; Aquila B; Augustin M; Chen H; Cheung T; Cook D; Drew L; Fauber BP; Glossop S; Grondine M; Hennessy E; Johannes J; Lee S; Lyne P; Mörtl M; Omer C; Palakurthi S; Pontz T; Read J; Sha L; Shen M; Steinbacher S; Wang H; Wu A; Ye M
J Med Chem; 2013 Mar; 56(5):1996-2015. PubMed ID: 23398453
[TBL] [Abstract][Full Text] [Related]
20. Potent and selective pyrazole-based inhibitors of B-Raf kinase.
Hansen JD; Grina J; Newhouse B; Welch M; Topalov G; Littman N; Callejo M; Gloor S; Martinson M; Laird E; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4692-5. PubMed ID: 18676143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
